Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05938478 · ClinicalTrials.gov registry record
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
A clinical trial of Atopic Dermatitis and Eczema, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT05938478 is a study of Atopic Dermatitis and Eczema that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 900 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05938478, a study of Atopic Dermatitis and Eczema, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the study. Participants will be asked to: * Complete 1-3 phone interviews during pregnancy and 1-2 phone interviews after delivery * Release medical records for pregnancy and for their child * Complete an online survey about their baby's development at 4 months and 12 months of age * May be asked to have a study doctor examine their child All information is collected remotely, and no visits to the study site are required.
Conditions Studied
Interventions
- DRUG Tralokinumab
Study Locations (1)
California
- University of California San Diego (UCSD) - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2035-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05938478
The ClinicalTrials.gov registry entry for NCT05938478 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (49% higher). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Tralokinumab is the first listed.
NCT05938478 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05938478 about?
NCT05938478 is a clinical study titled "Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT". The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differenc...
What is the current status of trial NCT05938478?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2022-12-08. Estimated completion is 2035-09-30.
What conditions does trial NCT05938478 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT05938478?
The interventions under investigation include: Tralokinumab (DRUG).
Who is sponsoring clinical trial NCT05938478?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05938478 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.